A Registered Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.
A Registered Observational Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.
1 other identifier
observational
500
1 country
1
Brief Summary
Color discrimination deficit is a common manifestation of Alzheimer's disease (AD). However, the pathophysiology of this dysfunction remains poorly understood. The aim of the present study was to evaluate color discrimination using the Farnsworth-Munsell 100 hue test in patients with AD and mild cognitive impairment (MCI), compared with age-matched control subjects. As a secondary aim, we evaluated whether the outcomes of these visual tests were associated with cognitive.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
November 28, 2022
CompletedFirst Posted
Study publicly available on registry
December 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedDecember 6, 2022
November 1, 2022
7.5 years
November 28, 2022
November 28, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
MoCA scores
The Montreal Cognitive Assessment (MoCA)
Baseline
Secondary Outcomes (1)
ACE-III scores
Baseline
Other Outcomes (1)
TES
Baseline
Study Arms (2)
Color discrimination deficit
Without Color discrimination deficit
Interventions
Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
Eligibility Criteria
The patients include who suffer from Neurodegenerative Disorders whether Color discrimination deficit or not.
You may qualify if:
- All patients underwent extensive clinical examination including thorough neurological and somatic examination by a specialized neurologist or geriatrician and extensive neuropsychological examination by a trained psychologist. AD was diagnosed according to the NINCDS-ADRDA criteria.
You may not qualify if:
- We excluded individuals with noncompensated somatic illnesses, a history of a psychiatric disorder, color blindness, ophthalmological pathology, severe cranial trauma, focal neurological signs or magnetic resonance imaging examinations suggestive of cerebrovascular disturbances.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 28, 2022
First Posted
December 6, 2022
Study Start
January 1, 2018
Primary Completion
July 1, 2025
Study Completion
July 1, 2025
Last Updated
December 6, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share